Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease

计划入组 299 人 · 首次发布于 2015 年 4 月 15 日

A Phase I Study of Lyso-thermosensitive Liposomal Doxorubicin and MR-HIFU for Pediatric Refractory Solid Tumors

计划入组 2 人 · 首次发布于 2015 年 8 月 31 日

Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors

计划入组 30 人 · 首次发布于 2004 年 10 月 8 日

LYSO-7

1-ACETYL-2-LYSO-SN-GLYCERO-3-PHOSPHOETHANOLAMINE

C₇H₁₇NO₇P

GB-G01

GBA Pharma GmbH

Germany

GBG Forschungs GmbH

Germany

G1 Therapeutics

United States

Spur Therapeutics' FLT201 Gene Therapy Shows Promise in Gaucher Disease with FDA Alignment on Phase 3

Spur Therapeutics to Present Two-Year Clinical Data for FLT201 Gene Therapy in Gaucher Disease at WORLDSymposium

Precision Genomic Profiling Reveals Multiple Molecular Diagnoses in Gaucher Disease Patients with Atypical Presentations